Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation
Therapeutic Advances in Medical Oncology · 2026-04 · 18
DOI: 10.1177/17588359261444616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 26.04.2026. Verfasst von Jing Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Clinical Key Specialty Construction Program, Fujian Research and Training Grants for Young and Middleaged Leaders in Healthcare, the Joint Funds for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Background
Combined radiotherapy and immunotherapy can enhance antitumor efficacy, but its effects on melanoma brain metastases (MBM) remain unclear.
Objectives
To evaluate the intracranial efficacy, safety, and exploratory immune biomarkers of zimberelimab combined with intracranial hypofractionated radiotherapy in patients with MBM.
Methods
Eligible patients were aged 18–75, had an Eastern Cooperative Oncology Group performance status of 0–2 and measurable brain metastases. Patients received 30–50 Gy/5–10 fractions intracranial hypofractionated radiotherapy and two cycles zimberelimab (240 mg every 3 weeks). The primary endpoint was the intracranial objective response rate (ORR). Secondary endpoints included the disease control rate, overall survival, progression-free survival (PFS), quality of life, safety and potential biomarkers. In addition, serum cytokines were profiled and linked to proteomics-based exploratory prognostic model constructed using the UK Biobank dataset.
Results
Between November 2022 and February 2025, 10 patients, with median age 60.5 years, completed the treatment, and their data were analyzed. The median intracranial metastatic lesion size was 2.4 cm (range 1.0–5.9 cm). The intracranial ORR was 70%, and intracranial disease control rate was 90%. The median overall survival and intracranial PFS were both 12 months, while the overall PFS was 10.5 months. The patients’ quality of life improved, without grade ⩾3 treatment-related adverse events. Furthermore, post-treatment increases in selected immune-related biomarkers, such as CXCL9, were descriptively associated with treatment response, and baseline levels showed exploratory associations with survival outcomes.
Conclusion
HFRT plus zimberelimab demonstrated promising intracranial activity, quality of life improvement, and acceptable early safety in patients with MBM and may potentially induce an abscopal antitumor effect. Exploratory immune analyses suggest that baseline immune readiness and therapy-induced immune activation may be associated with treatment benefit.
Design
This was a prospective, single-arm, open-label phase II study.
Trial registration
ChiCTR, ChiCTR2200057001. Registered 25 February 2022 ( https://www.chictr.org.cn/showproj.html?proj=153144 ).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China.
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China.
ORCID-Profile: Ting Zhang, Jieyuan Cai, Jinluan Li
Förderung
- the National Clinical Key Specialty Construction Program
- Fujian Research and Training Grants for Young and Middleaged Leaders in Healthcare
- the Joint Funds for the Innovation of Science and Technology, Fujian Province
- Natural Science Foundation of Fujian Province
Zitieren
APA
Lin, J., Zhang, T., Zeng, Y., Tang, L., Cai, J., Chen, L., Fang, J., Chen, Y., & Li, J. (2026). Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261444616
Vancouver
Lin J, Zhang T, Zeng Y, Tang L, Cai J, Chen L, et al. Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261444616
BibTeX
@article{Lin2026,
author = {Lin, Jing and Zhang, Ting and Zeng, Yibin and Tang, Lirui and Cai, Jieyuan and Chen, Ling and Fang, Jiazhen and Chen, Yu and Li, Jinluan},
title = {Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulation},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261444616}
}
EUVIMED